Compugen Ltd (CGEN)

$2.80 +0.19 (7.28%)
Market Cap 246.78M
Revenue (ttm) 72.76M
Net Income (ttm) 35.34M
EPS (ttm) N/A
PE Ratio 7.31
Forward PE N/A
Profit Margin 48.57%
Debt to Equity Ratio 0.00
Volume 580,100
Avg Vol 469,930
Day's Range N/A - N/A
Shares Out 94.55M
Stochastic %K 51%
Beta 2.79
Analysts Strong Sell
Price Target $5.83

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 765 8585
Fax: 972 3 765 8555
Website: cgen.com
Address:
Azrieli Center, Building D 26 Harokmim Street, Holon, Israel
TwitteringTom
TwitteringTom May. 21 at 8:19 PM
$CGEN 8 years in this, stilling holding... this thing sucks there i said it
1 · Reply
KoalaFlipper
KoalaFlipper May. 20 at 4:58 PM
$CGEN looks like it stays at 2,70 xD
0 · Reply
John_McClane911
John_McClane911 May. 19 at 7:45 PM
$CGEN
0 · Reply
wenmoon_stonks
wenmoon_stonks May. 19 at 2:44 PM
$CGEN backdrop is good, cash runway is good, pipeline is good, price action needs to catch up.
0 · Reply
Otus
Otus May. 19 at 1:36 PM
$CGEN it’s a shelf registration. They use it or they don’t. They don’t need it now. Looks to me like a buying opportunity.
0 · Reply
zerodayrounder
zerodayrounder May. 19 at 1:32 PM
$CGEN i thought these guys were funded out to 2029?
0 · Reply
DonCorleone77
DonCorleone77 May. 18 at 11:01 PM
$BALY $YALA $CGEN AFTER-HOURS MOVERS: - Currently Higher After Earnings: Agilysys (AGYS) up 16.2% Currently Also Higher: - Penguin Solutions (PENG) up 7,6% after naming David Heard, President of Network Infrastructure at Nokia, to Board - Nomad Foods (NOMD) up 2,1% after insider buy Currently Lower After Earnings: - XP Inc. (XP) down 3.3% - Bally's Corporation (BALY) down 2.1% - Yalla Group (YALA) down 2.5% Currently Also Lower: - Compugen (CGEN) down 0.4% after equity offering.
0 · Reply
MarketBeat
MarketBeat May. 18 at 2:09 PM
https://marketbeat.com/a/8661242/ $CGEN Compugen Q1 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 18 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-5-18-compugen-ltd-stock/ $CGEN Compugen Earnings Transcript
0 · Reply
KoalaFlipper
KoalaFlipper May. 18 at 12:13 PM
$CGEN
0 · Reply
Latest News on CGEN
Compugen price target lowered to $5 from $13 at Leerink

2026-05-21T10:11:15.000Z - 2 days ago

Compugen price target lowered to $5 from $13 at Leerink

Compugen Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 19, 2026, 10:00 AM EDT - 4 days ago

Compugen Transcript: Stifel 2026 Targeted Oncology Virtual Forum

Compugen files $400M mixed securities shelf

2026-05-18T20:06:28.000Z - 4 days ago

Compugen files $400M mixed securities shelf

Compugen Q1 Earnings Call Highlights

May 18, 2026, 10:09 AM EDT - 5 days ago

Compugen Q1 Earnings Call Highlights

Compugen Earnings Call Transcript: Q1 2026

May 18, 2026, 8:30 AM EDT - 5 days ago

Compugen Earnings Call Transcript: Q1 2026

Compugen Earnings release: Q1 2026

May 18, 2026, 8:30 AM EDT - 5 days ago

Compugen Earnings release: Q1 2026

Compugen Registration statement: Registration filing

May 18, 2026, 8:00 AM EDT - 5 days ago

Compugen Registration statement: Registration filing

Compugen reports Q1 EPS (8c) vs. (8c) last year

2026-05-18T11:05:06.000Z - 5 days ago

Compugen reports Q1 EPS (8c) vs. (8c) last year

Options Volatility and Implied Earnings Moves Today, May 18, 2026

2026-05-18T11:05:05.000Z - 5 days ago

Options Volatility and Implied Earnings Moves Today, May 18, 2026

BIDU DUOT GOSS NIU SACH TOYO YALA

Compugen Reports First Quarter 2026 Results

May 18, 2026, 7:00 AM EDT - 5 days ago

Compugen Reports First Quarter 2026 Results

Compugen Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 9 days ago

Compugen Slides: Corporate presentation

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

May 12, 2026, 7:00 AM EDT - 11 days ago

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

May 4, 2026, 7:00 AM EDT - 19 days ago

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Compugen Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 8:45 AM EDT - 5 weeks ago

Compugen Transcript: 25th Annual Needham Virtual Healthcare Conference

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:00 AM EDT - 6 weeks ago

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Compugen initiated with a Buy at Lake Street

2026-04-07T11:44:13.000Z - 6 weeks ago

Compugen initiated with a Buy at Lake Street

AZN GILD MRK

Compugen Slides: Corporate presentation

Mar 23, 2026, 8:00 AM EDT - 2 months ago

Compugen Slides: Corporate presentation

Compugen Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:40 AM EDT - 2 months ago

Compugen Transcript: Leerink Global Healthcare Conference 2026

Compugen Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:30 AM EST - 2 months ago

Compugen Earnings Call Transcript: Q4 2025

Compugen Annual report: Q4 2025

Mar 2, 2026, 8:30 AM EST - 2 months ago

Compugen Annual report: Q4 2025

Compugen Earnings release: Q4 2025

Mar 2, 2026, 8:30 AM EST - 2 months ago

Compugen Earnings release: Q4 2025

Compugen reports Q4 EPS 60c vs. (7c) last year

2026-03-02T12:22:05.000Z - 2 months ago

Compugen reports Q4 EPS 60c vs. (7c) last year

Compugen Reports Fourth Quarter and Full Year 2025 Results

Mar 2, 2026, 7:00 AM EST - 2 months ago

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 2:00 PM EST - 3 months ago

Compugen Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Compugen to Participate in Upcoming Investor Conferences

Feb 19, 2026, 7:00 AM EST - 3 months ago

Compugen to Participate in Upcoming Investor Conferences

Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026

Feb 17, 2026, 7:00 AM EST - 3 months ago

Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Feb 12, 2026, 7:00 AM EST - 3 months ago

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Compugen Slides: Corporate presentation

Jan 11, 2026, 7:00 AM EST - 4 months ago

Compugen Slides: Corporate presentation

Compugen initiated with a Buy at H.C. Wainwright

2026-01-07T11:10:47.000Z - 4 months ago

Compugen initiated with a Buy at H.C. Wainwright

Compugen and AstraZeneca agree to monetize rilvegostomig future royalties

2025-12-17T12:12:00.000Z - 5 months ago

Compugen and AstraZeneca agree to monetize rilvegostomig future royalties

AZN

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Dec 17, 2025, 7:00 AM EST - 5 months ago

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Compugen Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 3:20 PM EST - 6 months ago

Compugen Transcript: Stifel 2025 Healthcare Conference

Compugen Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:30 AM EST - 6 months ago

Compugen Earnings Call Transcript: Q3 2025

Compugen Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 6 months ago

Compugen Earnings release: Q3 2025

Compugen reports Q3 EPS (7c), consensus (9c)

2025-11-10T12:23:25.000Z - 6 months ago

Compugen reports Q3 EPS (7c), consensus (9c)

Compugen Reports Third Quarter 2025 Results

Nov 10, 2025, 7:00 AM EST - 6 months ago

Compugen Reports Third Quarter 2025 Results

Compugen Slides: Corporate presentation

Nov 7, 2025, 7:00 AM EST - 7 months ago

Compugen Slides: Corporate presentation

Compugen to Participate in Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 7 months ago

Compugen to Participate in Stifel 2025 Healthcare Conference

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Oct 13, 2025, 7:00 AM EDT - 7 months ago

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Compugen to Present at SITC 2025

Oct 6, 2025, 7:00 AM EDT - 8 months ago

Compugen to Present at SITC 2025

Compugen Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 16, 2025, 11:30 AM EDT - 8 months ago

Compugen Transcript: Q3 Investor Summit Group Virtual Conference 2025

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Sep 8, 2025, 7:00 AM EDT - 9 months ago

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Compugen Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 9 months ago

Compugen Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:00 AM EDT - 9 months ago

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Compugen price target raised to $13 from $10 at Leerink

2025-08-07T11:35:33.000Z - 10 months ago

Compugen price target raised to $13 from $10 at Leerink

AZN

Compugen Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

Compugen Earnings Call Transcript: Q2 2025

Compugen Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

Compugen Earnings release: Q2 2025

Compugen reports Q2 EPS (8c), consensus (9c)

2025-08-06T11:26:38.000Z - 10 months ago

Compugen reports Q2 EPS (8c), consensus (9c)

Compugen Reports Second Quarter 2025 Results

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Compugen Reports Second Quarter 2025 Results

Compugen Slides: Investor presentation

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Compugen Slides: Investor presentation

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Jul 28, 2025, 7:00 AM EDT - 10 months ago

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Jul 23, 2025, 7:00 AM EDT - 10 months ago

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Compugen begins dosing in ovarian cancer trial

2025-07-21T11:05:54.000Z - 10 months ago

Compugen begins dosing in ovarian cancer trial

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Jul 21, 2025, 7:00 AM EDT - 10 months ago

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

Jun 12, 2025, 7:00 AM EDT - 1 year ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

Compugen Earnings Call Transcript: Q1 2025

May 19, 2025, 8:30 AM EDT - 1 year ago

Compugen Earnings Call Transcript: Q1 2025

Compugen Earnings release: Q1 2025

May 19, 2025, 8:30 AM EDT - 1 year ago

Compugen Earnings release: Q1 2025

Options Volatility and Implied Earnings Moves Today, May 19, 2025

2025-05-19T11:05:25.000Z - 1 year ago

Options Volatility and Implied Earnings Moves Today, May 19, 2025

CBAT GILT GSL NIU QFIN RYAAY TCOM

Compugen Reports First Quarter 2025 Results

May 19, 2025, 7:00 AM EDT - 1 year ago

Compugen Reports First Quarter 2025 Results

Compugen Slides: Corporate presentation

May 16, 2025, 7:00 AM EDT - 1 year ago

Compugen Slides: Corporate presentation

Compugen appoints Eran Ophir as CEO, announces leadership transitions

2025-05-13T11:12:07.000Z - 1 year ago

Compugen appoints Eran Ophir as CEO, announces leadership transitions

Compugen Announces Leadership Transitions Effective September 2025

May 13, 2025, 7:00 AM EDT - 1 year ago

Compugen Announces Leadership Transitions Effective September 2025

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Compugen Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 9, 2025, 12:00 PM EDT - 1 year ago

Compugen Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Compugen Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Compugen Transcript: 24th Annual Needham Virtual Healthcare Conference

Compugen Transcript: H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Conference

Apr 2, 2025, 9:30 AM EDT - 1 year ago

Compugen Transcript: H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Conference

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Compugen Slides: Corporate presentation

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Compugen Slides: Corporate presentation

Compugen Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Compugen Transcript: Leerink’s Global Healthcare Conference 2025

Compugen Earnings Call Transcript: Q4 2024

Mar 4, 2025, 8:30 AM EST - 1 year ago

Compugen Earnings Call Transcript: Q4 2024

Compugen Annual report: Q4 2024

Mar 4, 2025, 8:30 AM EST - 1 year ago

Compugen Annual report: Q4 2024

Compugen Earnings release: Q4 2024

Mar 4, 2025, 8:30 AM EST - 1 year ago

Compugen Earnings release: Q4 2024

Compugen reports Q4 EPS (7c) vs. 11c last year

2025-03-04T12:06:24.000Z - 1 year ago

Compugen reports Q4 EPS (7c) vs. 11c last year

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 4, 2025, 7:00 AM EST - 1 year ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 26, 2025, 7:00 AM EST - 1 year ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 18, 2025, 7:00 AM EST - 1 year ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Compugen Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Compugen Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 1 year ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compugen initiated with an Outperform at Oppenheimer

2025-01-13T13:01:57.000Z - 1 year ago

Compugen initiated with an Outperform at Oppenheimer

AZN GILD

Compugen Slides: Corporate presentation

Jan 12, 2025, 7:00 AM EST - 1 year ago

Compugen Slides: Corporate presentation

Compugen says first patient dosed in Phase 1 trial of COM503

2025-01-08T12:25:57.000Z - 1 year ago

Compugen says first patient dosed in Phase 1 trial of COM503

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Jan 8, 2025, 7:00 AM EST - 1 year ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Compugen announces USPTO grants new patent for use of COM902

2024-11-27T12:06:19.000Z - 1 year ago

Compugen announces USPTO grants new patent for use of COM902

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Compugen Slides: Corporate presentation

Nov 27, 2024, 7:00 AM EST - 1 year ago

Compugen Slides: Corporate presentation

Compugen Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 8:35 AM EST - 1 year ago

Compugen Transcript: Stifel 2024 Healthcare Conference

Compugen Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Compugen Earnings Call Transcript: Q3 2024

Compugen Earnings release: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Compugen Earnings release: Q3 2024

Compugen Reports Third Quarter 2024 Results

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Third Quarter 2024 Results

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 11, 2024, 7:00 AM EST - 1 year ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Compugen to Present New Clinical Data at SITC 2024

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data at SITC 2024

Compugen to Present at Single Cell Genomics 2024 Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Single Cell Genomics 2024 Conference

Compugen Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Compugen Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Compugen Earnings Call Transcript: Q2 2024

Compugen Earnings release: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Compugen Earnings release: Q2 2024

Compugen Reports Second Quarter 2024 Results

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports Second Quarter 2024 Results

Compugen Slides: Corporate presentation

Aug 5, 2024, 7:00 AM EDT - 1 year ago

Compugen Slides: Corporate presentation

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Compugen to Present at Upcoming Antibody Industrial Symposium

Jun 17, 2024, 7:00 AM EDT - 2 years ago

Compugen to Present at Upcoming Antibody Industrial Symposium

Compugen Slides: Corporate presentation

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Compugen Slides: Corporate presentation

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

May 30, 2024, 7:00 AM EDT - 2 years ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

Compugen Earnings Call Transcript: Q1 2024

May 20, 2024, 8:30 AM EDT - 2 years ago

Compugen Earnings Call Transcript: Q1 2024

Compugen Earnings release: Q1 2024

May 20, 2024, 8:30 AM EDT - 2 years ago

Compugen Earnings release: Q1 2024

Compugen Reports First Quarter 2024 Results

May 20, 2024, 7:00 AM EDT - 2 years ago

Compugen Reports First Quarter 2024 Results

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 16, 2024, 7:00 AM EDT - 2 years ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

Compugen Appoints David Silberman as Chief Financial Officer

May 15, 2024, 7:00 AM EDT - 2 years ago

Compugen Appoints David Silberman as Chief Financial Officer

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

TwitteringTom
TwitteringTom May. 21 at 8:19 PM
$CGEN 8 years in this, stilling holding... this thing sucks there i said it
1 · Reply
KoalaFlipper
KoalaFlipper May. 20 at 4:58 PM
$CGEN looks like it stays at 2,70 xD
0 · Reply
John_McClane911
John_McClane911 May. 19 at 7:45 PM
$CGEN
0 · Reply
wenmoon_stonks
wenmoon_stonks May. 19 at 2:44 PM
$CGEN backdrop is good, cash runway is good, pipeline is good, price action needs to catch up.
0 · Reply
Otus
Otus May. 19 at 1:36 PM
$CGEN it’s a shelf registration. They use it or they don’t. They don’t need it now. Looks to me like a buying opportunity.
0 · Reply
zerodayrounder
zerodayrounder May. 19 at 1:32 PM
$CGEN i thought these guys were funded out to 2029?
0 · Reply
DonCorleone77
DonCorleone77 May. 18 at 11:01 PM
$BALY $YALA $CGEN AFTER-HOURS MOVERS: - Currently Higher After Earnings: Agilysys (AGYS) up 16.2% Currently Also Higher: - Penguin Solutions (PENG) up 7,6% after naming David Heard, President of Network Infrastructure at Nokia, to Board - Nomad Foods (NOMD) up 2,1% after insider buy Currently Lower After Earnings: - XP Inc. (XP) down 3.3% - Bally's Corporation (BALY) down 2.1% - Yalla Group (YALA) down 2.5% Currently Also Lower: - Compugen (CGEN) down 0.4% after equity offering.
0 · Reply
MarketBeat
MarketBeat May. 18 at 2:09 PM
https://marketbeat.com/a/8661242/ $CGEN Compugen Q1 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 18 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-5-18-compugen-ltd-stock/ $CGEN Compugen Earnings Transcript
0 · Reply
KoalaFlipper
KoalaFlipper May. 18 at 12:13 PM
$CGEN
0 · Reply
KoalaFlipper
KoalaFlipper May. 18 at 12:07 PM
$CGEN still bullish on Compugen Ltd very undevalued company!
0 · Reply
ARMRreport
ARMRreport May. 18 at 11:43 AM
That 👇 is the $MXL pattern [ARMR Turnaround] $CGEN
0 · Reply
ARMRreport
ARMRreport May. 18 at 11:43 AM
$CGEN earnings release. They reported about $135 million in cash, which gives them runway into 2029. Their key trials are progressing—COM701 is enrolling in ovarian cancer, AstraZeneca's pushing rilvegostomig in multiple Phase 3s with new data coming at ASCO, and the Gilead partnered program is moving forward
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 18 at 11:07 AM
$CGEN Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.08 • Reported revenue of $2.18M down -4.73% YoY • Compugen expects its solid financial position with cash runway to fund operations into 2029, enabling advancement of its differentiated immuno-oncology pipeline and leveraging its AI/ML platform.
0 · Reply
hubal
hubal May. 18 at 11:05 AM
$CGEN https://www.prnewswire.com/news-releases/compugen-reports-first-quarter-2026-results-302774535.html
0 · Reply
zerodayrounder
zerodayrounder May. 16 at 6:23 PM
$CGEN so with all the biotech M&A how long does its BP partners let this thing hang out there as a standalone? AZN relying pretty heavily on CGEN licensed molecule for like 10 P3 trials, no?
0 · Reply
KoalaFlipper
KoalaFlipper May. 16 at 10:20 AM
$CGEN 2 days til earnings report lets goo cant wait 😁🚀📈
0 · Reply
TwitteringTom
TwitteringTom May. 15 at 8:59 PM
$CGEN dip before earnings? love it , lets GO MONDAY LETS GO
1 · Reply
Otus
Otus May. 15 at 2:00 PM
$CGEN I hate these low volume drops. The perils of thinly traded stocks. Hopefully they announce something of substance with the earnings. If not expect further downward price pressure. It would be a buying opportunity.
0 · Reply
wenmoon_stonks
wenmoon_stonks May. 14 at 7:05 PM
$CGEN let's go 🚀
0 · Reply
KoalaFlipper
KoalaFlipper May. 14 at 4:11 PM
$CGEN plz stay at 3 😅📈🚀
0 · Reply
AGC_Trader
AGC_Trader May. 14 at 2:15 PM
$CGEN looks like it's ready to surge
0 · Reply